

HPV versus cytology screening in South-Africa: the way forward

Dr. Suzette M Jordaan



South Africa

- 9 provinces managed autonomously; diverse population –
 55 million plus about 5m legal/illegal immigrants and migrant workers
- 11 official languages; rural/suburban and urban areas mountainous areas as well as desert.
- Rural areas 43% of population
- Long distances to travel to health care facilities.
- Rural health care facilities have a shortage of basic equipment, e.g. light sources; swabs; specula



Cervical cancer


- Cervical cancer remains the second most common cancer diagnosed in women in South Africa with an estimated 7.735 new cases in 2012, with 4.248 women dying from the disease.
- Like the rest of Africa, the country has a chronic shortage of health care workers



Shortage of medical staff

- More than 70% of South Africa's medical staff works in private health care facilities. South Africa has one doctor for every 3 707 to 4 918 of their citizens. This ratio in the developed countries is an average of one doctor for every 242 to 539 of its inhabitants.
- Patients in rural areas suffer due to these shortages as South Africa struggles to attract and retain enough medical staff to provide health services not only in the urban areas, but particularly in remote locations. In South Africa, 43.6% of the population lives in rural areas, but only about 12% of the country's doctor's work in rural healthcare facilities.

Health care facilities and laboratories



Health care facilities per province

In South Africa 4 526 health facilities

Gauteng -538

KwaZulu Natal -739

Eastern Cape -1101

Limpopo -612

Mpumalanga -381


Northwest -304

• Free State -331

Northern Cape -231

Western Cape -476 feed into 12 cytology laboratories

Population groups



SASGO CONGRESS

HIV

- South Africa has the largest expanding HIV burden in the world and it is estimated that 6.3 million South Africans are currently living with HIV/AIDS, of whom 60% are women
- HIV significantly increases the risk of persistent HPV infections
- the development of cervical cancer is faster in HIVpositive women.



Effect of HIV on cytology diagnosis

abnormal Cytology results per age group - HIV-/HIV+									
Age group	ASC-US %		LSIL %		HSIL plus	s ASC-H %	Malignant %		
	HIV-	HIV+	HIV-	HIV+	HIV-	HIV+	HIV-	HIV+	
20-25	1.8	3.8	1.8	5.2	0.4	2.2	0.0	0.1	
26-30	2.2	6.0	1.8	8.7	1.1	6.3	0.2	0.8	
31-35	2.0	6.4	1.8	8.7	1.6	8.8	0.4	2.0	
36-40	1.6	5.5	1.3	7.3	1.3	8.7	0.6	3.5	
41-45	1.6	3.9	1.2	4.4	1.2	5.8	0.7	3.0	
46-50	1.4	2.7	0.8	2.5	1.0	3.7	1.4	2.7	
51-55	1.0	1.5	0.4	1.2	0.9	1.9	2.8	2.7	
56-60	0.7	0.8	0.3	0.5	0.5	1.0	2.8	1.4	
61+	1.6	1.2	0.6	1.0	1.2	1.5	4.1	2.1	



HIV and HPV

- HIV significantly increases the risk of persistent HPV infections
- HIV-infected women have greater rates of pre-invasive and invasive cervical cancer rates whereas HPV infection promotes the acquisition of HIV
- the development of cervical cancer is faster in HIVpositive women.



Prevention strategies





Prevention strategies - Primary

- To prevent women from acquiring HPV infection
- Change sexual practices, e.g. condoms, monogamy
- HPV vaccination school-based program
- April 2014 17 807 public schools
- March-April and September-October 2014 419.589 (93.2%) and 329.665 (73.3%) girls were vaccinated respectively
- in 2015, 356.228 (79%) received the first vaccine dose while 283.453 (63%) received both doses.

Secondary prevention

- Secondary prevention is to prevent precursor lesions from becoming invasive carcinoma

Modalities include:

- -Cervical cytology 12 NHLS Cytology laboratories
- LBC currently implemented in public sector
- HPV screening available at Private laboratories
- VIA currently not encouraged at primary care facilities



Prevention strategy - Tertiary

- Shortage of health care workers and much needed equipment
- Long waiting lists at Colposcopy clinics
- Women from rural areas usually arrive for treatment when it is already too late



Challenges and progress of screening policies


- National cancer control program (2000 /2004-till 2017)
- HIV Counseling and Testing (HCT) (2011) CD4 count < 250
- HIV Counseling and Testing HCT (2014)
 CD4 count < 500
- Universal Test and Treat (2016) regardless of CD4 count



WAKA

National cancer control program 2000

- Cervical cancer screening program 2000 re-launched in 2004
- Screen 70% of asymptomatic women 30 y and older
- Target 6.866.222 686.622 per annum (10 y)




HIV Counseling and Treatment screening program (HCT)

- HCT screening program announced April 2011
- All women tested positive for HIV (CD4 < 250) must have a Pap smear taken

	HIV	+ women with	CD4 count ≤250)/μΙ
Year	2011/12	2012/13	2013/14	2014/15
Total	683,913	573,275	536,921	516,287

Women tested HIV positive with CD4 count ≤250/µl

Women tested HIV positive with CD4 count ≤250/µl






HIV Counsel and Treat program (HCT) and Universal Test and Treat program (UTT)

- HCT program 2014 CD4 count <500µl
- UTT program announced September 2016 all women tested positive for HIV must have a Pap smear taken regardless of CD4 count

	W	omen tested l	HIV Viral load	positive at the	- NHI S lahora	torv
Year	2010/11	2011/12	2012/13	2013/14	2014/15	2015/16
Total	462.339	838.461	851.991	918.560	895.749	1.012.053
Africa	GLGGO GONGDEGO					

Women tested HIV positive with CD4 count ≤500/µl






National South African data


 According to the 2011 Census data there are 16.613.832 women over the age of 20 and 11.417.301 women over the age of 30 eligible for Pap smears in South Africa

Pap smear results nationally March 2005 to December 2016





Age specific incidence of Cervical carcinoma





Provincial statistics


Province	Females Aged 30+.	Pap smears screened	Pap smear coverage % women aged 20+	Pap smear coverage % women aged 30+	% ASC- US	% LSIL	% HSIL	% MAL	% Unsuit
Western Cape	1.412769	1.102.953	55%	78%	3.7	8.8	4.1	0.2	2
Free State	625.353	383.959	43%	61%	3.8	8.2	3.2	0.9	7
North West	742.755	446.616	42%	60%	2.3	5.8	3.4	0.4	4
Gauteng	2.786.427	1.585.108	38%	57%	4.4	15.8	8.2	0.3	2
Limpopo	1.157.190	636.610	38%	55%	3.0	5.3	3.1	0.1	1
Mpumalanga	822.735	428.645	35%	52%	3.6	4.4	7.0	0.5	1
Northern Cape	257.361	126.095	35%	49%	2.6	5.5	2.1	0.7	6
KwaZulu-Natal	2.133.438	967.907	30%	45%	3.5	9.8	5.8	0.4	3
Eastern Cape	1.479.258	599.879	29%	41%	4.8	6.3	5.0	1.1	2

Rural/Suburban/Urban

	Nr of smears	% screened	Adeq	ASC-US	LSIL	HSIL	Malignancy	Unsuita ble
Rural	1.341.743	21.4%	55%	3.6%	6.6%	5.0%	0.7%	2%
Suburban	1.070.877	17.1%	68%	3.4%	7.3%	4,5%	0.4%	3%
Urban	3.853.611	61.5%	71%	4.0%	11.0%	6.3%	0.3%	2%
TOTAL	6.266.231							




Choropleth map: Districts and sub-districts HSIL





Choropleth map: Districts and sub-districts – cervical malignancy





Gauteng Province: District and subdistrict

	City of Tshwane Metro									
Sub District	Smears	%	%	%	%	%	%			
		Adequacy	ASC	LSIL	HSIL	MAL	Unsuita			
			-US				ble			
Tshwane 1 Health Sub-District	107.489	79%	0.9	6.2	3.6	0.2	1			
Tshwane 2 Health Sub-District	37.871	72 %	1.6	5.4	3.5	0.2	1			
Tshwane 3 Health Sub-District	113.808	74%	3.7	4.6	6.3	0.8	1			
Tshwane 4 Health Sub-District	33.512	78%	4.5	3.7	7.1	0.5	1			
Tshwane 5 Health Sub-District	4.492	46%	4.6	4.5	6.5	0.3	1			
Tshwane 6 Health Sub-District	66.587	73%	5.3	4.8	8.2	0.6	1			
Tshwane 7 Health Sub-District	10.367	58%	5.1	4.8	7.8	0.4	1			
City of Tshwane	2.201	69%	3.5	7.1	5.1	0.0	1			



Western Cape province

	Central Karoo								
Sub District	Urban/ Rural	Cases	% Adequacy	% ASC- US	% LSIL	% HSIL	% MALIG	% Unsuit able	
Laingsburg	Suburban	1.456	85%	5.2%	6.6%	4.1%	0.9%	4%	
Prince Albert	Rural	2.193	64%	2.4%	5.6%	2.3%	0.5%	2%	
Beaufort West	Urban	9.343	70%	2.5%	7.6%	3.3%	0.2%	1%	




Eastern Cape province

Amathole								
Sub District	Urban / Rural	Cases	% MALIG					
Mnquma	Rural	18.031	9.6%					
Mbashe	Rural	22.903	0.8%					
Amahlati	Rural	25.973	0.2%					
Nkonkobe	Rural	21.667	0.2%					



WAKA

Cervical cancer prevention in SA: what do we do now?



What have we learnt?

- Before a successful screening program is introduced one needs to have some base-level data e.g. number of women in target population; rates of cervical lesions nationally as well as district and sub-district level, risks e.g. prevalence rates of HPV, HIV etc.
- Appropriate new technologies for SA include platforms that offer good detection rate of abnormalities, faster TAT, ability to perform ancillary studies, COST.
- Do not repeat previous screening mistakes, e.g. poor coverage, lack of staffing and equipment, screening but no treatment.



Results of LBC tender

- The Hologic ThinPrep system was found to be more suitable for the NHLS.
 - Ease of use
 - Automation
 - Better turn around time
 - Easier to screen mono-layered smear
 - Automated screening









SASGO CONGRESS 31 AUGUST - 2 SEPTEMBER 2018 Spier Estate, Stellenbosch Cape Town

Hologic autoloader





36

Comparison of HPV equipment

Equipment evaluated for HPV	Batch size	Measured throughput per 8hr day	Walk-away time per 8 hr. day	Ability to do HIV or TB tests on this platform
Panther – IlexSA	16	278 500 in 12hr	SurePath – 2hrs ThinPrep – 4hrs	HPV, HIV
BD Viper™ LT	30	60 90 in 12hr	NIL	HPV
Qiagen - QiaSymphony and Rapid Capture System (RCS) Hybrid Capture II		176	NIL STM – 2 hrs.	HPV



Comparison of HPV equipment


Equipment evaluated for HPV	Batch size	Measured throughput per 8hr day	Walk-away time per 8 hr. day	Ability to do HIV or TB tests on this platform
Roche Cobas 4800 and Z4800	24	88	3hrs	HPV,HIV
		110 in 12hr		
Cepheid -GeneXpert	1 per	8 per	Depends on nr	HPV,TB, HIV
	module	module	of modules	
ABBOTT - m2000sp and	94	188	NIL	HPV, HIV
m2000rt			Prolonged Prep	
			time	

HPV tests

HPV DNA / mRNA

Discriminatory

Non-discriminatory





HPV test requirement

HPV test would be required which has been clinically validated, robust, fully automated, fast, affordable, single assay with an adjustable cut-off for detection, having a cell control and preferentially linked to a genotyping method.



HPV prevalence – Study KZN 2004 -2007

• Study in KZN – rural setting - samples were collected from all 224 enrolled Black African women - 57% of women from rural area. HPV prevalence was 76.3% (171/224) overall and 70.5% in the rural setting. The prevalence of high-risk genotypes in this study was 54.5%. prevalence was high both among women <18 years (70.3%) and >18 years (77.5%) old. The overall HPV prevalence of 76.3% in this study is almost 3-4 fold higher than other reported estimates. The proportion of women infected with the high-risk vaccine genotypes (HPV16 and/or 18) was 21% (47/224)

HPV prevalence – GP - 2013

- 1 472 women from the Gauteng Province attending five urban and peri-urban public health sector clinics.
- In this study, the prevalence of HPV DNA was 74.6% with high risk HPV (hrHPV) DNA in 54.3%.
- HPV type 16 and/or 18 was found in 19.5% of women.
 Specimens for HPV genotyping were either healthcare worker-collected dry cervical swabs (N=951) or patient-collected tampon specimens (N=573).



HPV prevalence – CT - 2014

- showed a much lower overall prevalence of HPV DNA of 25.4% of 9429 study participants.
- One or more high-risk HPV genotypes was present in 78.5% (1848/2 354) of the HPV positive women tested which is an overall hrHPV prevalence of 19.6%.




Way forward

- Establish Strengths, Weaknesses,
 Opportunities and Threats (SWOT)
- Establish the population, prevalence rates per age groups
- Learn from cervical cancer screening program
- Decide whether to strengthen what we have or implement new technologies
- Evaluate new technologies for suitability



Prevalence rates -LBC






"ONE SIZE DOES NOT FIT ALL"



STATUS QUO - 2022



SASGO CONGRESS 31 AUGUST - 2 SEPTEMBER 2018

Thank you

